We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Enhancing siRNA Quantification in Plasma With Microflow Liquid Chromatography

Oligonucleotide therapeutics such as antisense oligonucleotides (ASOs) and small interfering RNA (siRNA) are becoming increasingly important due to their high specificity and capability for treating formerly undruggable targets.

Liquid chromatography mass spectrometry (LC-MS) has been routinely employed for bioanalytical studies of such oligonucleotides due to its high specificity, relatively short method development time and metabolite identification capability. However, the sensitivity is limited compared to other platforms, therefore we will demonstrate the benefits of using microflow LC for the quantification of GalNAc or lipid modified siRNAs in plasma.

Attend this webinar to:

  • Learn about the importance of siRNA as drug candidates
  • Understand why lipid and GalNAc conjugated siRNA are investigated
  • Understand the value of solid-phase extraction to remove siRNA from plasma
  • Discover the benefits of microflow LC
Lijuan Kang
Lijuan Kang
Sr. Scientist, DMPK, Janssen R&D, Janssen: Pharmaceutical Companies of Johnson & Johnson